COVIP: Outcomes and Prognostic Factors in COVID-19

Sponsor
Heinrich-Heine University, Duesseldorf (Other)
Overall Status
Recruiting
CT.gov ID
NCT04321265
Collaborator
(none)
1,500
7
36.4
214.3
5.9

Study Details

Study Description

Brief Summary

The primary aim is to study the short-term outcome of elderly ICU patients (≥ 70 years) suffering from COVID-19 using a multicenter and multi-national approach. The secondary aim is to investigate the properties of a simple frailty scale in this cohort, and in particular if this is an instrument that can be used for outcome prediction in this group. In addition, various other parameters of potential relevance for older critically ill patients will be studied.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study started in March 2020 and included until summer 2021 nearly 4000 patients. Several comprehensive analyses were conducted and published. Subsequently, in December 2021 the protocol was slightly changed and recruitment continues in 2022.

    Data are collected regarding: Pre-Admission life conditions with Frailty (Clinical Frailty Scale, CFSF.R.A.I.L Score); vaccination status; ICU-Admission (e.g. SOFA), ICU-Treatment, Survival (30 day and 3 months).

    Data are collected electronically through an e-CRF and with baseline documentation of the ICU. The database is located in Denmark, at the Department of Epidemiology, University of Aarhus. Each ICU will only have access through the database of their own patients, and patient ID is not registered (Names, birth-date or social security numbers) so it is in that sense anonymous.

    The goal is to recruit at up to 400 ICUs that will continuously collect data. The COVIP Study had two different previous recruitment periods. Period 1 (march to May 2020) finished representing the first wave of the pandemic in most countries. The second recruitment period has been defined being from September 1st to December 31st 2020 representing the second wave in most countries. Recruitment in 2021 also continued until the summer without allocating a specific recruitment period. However, the third recruitment period opened January 1st 2022 and is still ongoing.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients
    Actual Study Start Date :
    Mar 19, 2020
    Anticipated Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Mar 31, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Survival [up to 30 days]

    Secondary Outcome Measures

    1. Frailty [pre-admission]

      Frailty will be measured by using the Clinical frailty scale (CFS) a global clinical measure of fitness and frailty in elderly people (1=very fit to 9= terminally ill)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    70 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Age > 70 years

    2. ICU-Admission

    3. Infection with SARS-CoV-2

    Exclusion Criteria:
    1. Age <70 years

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Intensive Care, Aarhus University Hospital Aarhus Denmark
    2 Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale Paris France
    3 INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Paris France
    4 Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Paris France
    5 Division of Cardiology, Pulmonary Disease and Vascular Medicine Duesseldorf Germany 40225
    6 Department of Anaestesia and Intensive Care, Haukeland University Hospital Bergen Norway
    7 Department of Clinical Medecine,University of Bergen Bergen Norway

    Sponsors and Collaborators

    • Heinrich-Heine University, Duesseldorf

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Heinrich-Heine University, Duesseldorf
    ClinicalTrials.gov Identifier:
    NCT04321265
    Other Study ID Numbers:
    • 20-004
    First Posted:
    Mar 25, 2020
    Last Update Posted:
    Apr 27, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Heinrich-Heine University, Duesseldorf
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 27, 2022